Compare IPGP & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPGP | PGEN |
|---|---|---|
| Founded | 1990 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.8B |
| IPO Year | 2000 | 2013 |
| Metric | IPGP | PGEN |
|---|---|---|
| Price | $68.28 | $4.54 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 4 |
| Target Price | ★ $106.43 | $14.00 |
| AVG Volume (30 Days) | 337.3K | ★ 7.3M |
| Earning Date | 11-03-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 117.85 | N/A |
| EPS | ★ 0.63 | 0.12 |
| Revenue | ★ $1,003,777,000.00 | $230,981,000.00 |
| Revenue This Year | $11.67 | $2,335.22 |
| Revenue Next Year | $8.38 | $85.34 |
| P/E Ratio | $112.23 | ★ $38.67 |
| Revenue Growth | ★ 2.73 | N/A |
| 52 Week Low | $61.59 | $3.04 |
| 52 Week High | $155.82 | $8.98 |
| Indicator | IPGP | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 42.26 | 34.68 |
| Support Level | $61.59 | $3.65 |
| Resistance Level | $79.69 | $5.75 |
| Average True Range (ATR) | 3.56 | 0.47 |
| MACD | 0.00 | -0.08 |
| Stochastic Oscillator | 40.30 | 19.48 |
IPG Photonics Corp is a vertically integrated developer and manufacturer of high-performance fiber lasers, laser and non-laser systems, fiber amplifiers, diode lasers, and related optical components. Its products are used in diverse applications in the manufacturing, automotive, industrial, aerospace, semiconductor, and consumer end markets. The company sells its products globally to original equipment manufacturers (OEMs), system integrators, and end users. Additionally, it manufactures complementary products used with its lasers, including optical delivery cables, fiber couplers, beam switches, optical processing heads, in-line sensors, and chillers. Geographically, the company generates maximum revenue from North America, followed by China, Japan, Germany, and other markets.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.